Cargando…
Repurposing of the Drug Tezosentan for Cancer Therapy
Tezosentan is a vasodilator drug that was originally developed to treat pulmonary arterial hypertension. It acts by inhibiting endothelin (ET) receptors, which are overexpressed in many types of cancer cells. Endothelin-1 (ET1) is a substance produced by the body that causes blood vessels to narrow....
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297528/ https://www.ncbi.nlm.nih.gov/pubmed/37367074 http://dx.doi.org/10.3390/cimb45060325 |
_version_ | 1785063903478153216 |
---|---|
author | Ribeiro, Eduarda Vale, Nuno |
author_facet | Ribeiro, Eduarda Vale, Nuno |
author_sort | Ribeiro, Eduarda |
collection | PubMed |
description | Tezosentan is a vasodilator drug that was originally developed to treat pulmonary arterial hypertension. It acts by inhibiting endothelin (ET) receptors, which are overexpressed in many types of cancer cells. Endothelin-1 (ET1) is a substance produced by the body that causes blood vessels to narrow. Tezosentan has affinity for both ET(A) and ET(B) receptors. By blocking the effects of ET1, tezosentan can help to dilate blood vessels, improve the blood flow, and reduce the workload on the heart. Tezosentan has been found to have anticancer properties due to its ability to target the ET receptors, which are involved in promoting cellular processes such as proliferation, survival, neovascularization, immune cell response, and drug resistance. This review intends to demonstrate the potential of this drug in the field of oncology. Drug repurposing can be an excellent way to improve the known profiles of first-line drugs and to solve several resistance problems of these same antineoplastic drugs. |
format | Online Article Text |
id | pubmed-10297528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102975282023-06-28 Repurposing of the Drug Tezosentan for Cancer Therapy Ribeiro, Eduarda Vale, Nuno Curr Issues Mol Biol Review Tezosentan is a vasodilator drug that was originally developed to treat pulmonary arterial hypertension. It acts by inhibiting endothelin (ET) receptors, which are overexpressed in many types of cancer cells. Endothelin-1 (ET1) is a substance produced by the body that causes blood vessels to narrow. Tezosentan has affinity for both ET(A) and ET(B) receptors. By blocking the effects of ET1, tezosentan can help to dilate blood vessels, improve the blood flow, and reduce the workload on the heart. Tezosentan has been found to have anticancer properties due to its ability to target the ET receptors, which are involved in promoting cellular processes such as proliferation, survival, neovascularization, immune cell response, and drug resistance. This review intends to demonstrate the potential of this drug in the field of oncology. Drug repurposing can be an excellent way to improve the known profiles of first-line drugs and to solve several resistance problems of these same antineoplastic drugs. MDPI 2023-06-11 /pmc/articles/PMC10297528/ /pubmed/37367074 http://dx.doi.org/10.3390/cimb45060325 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ribeiro, Eduarda Vale, Nuno Repurposing of the Drug Tezosentan for Cancer Therapy |
title | Repurposing of the Drug Tezosentan for Cancer Therapy |
title_full | Repurposing of the Drug Tezosentan for Cancer Therapy |
title_fullStr | Repurposing of the Drug Tezosentan for Cancer Therapy |
title_full_unstemmed | Repurposing of the Drug Tezosentan for Cancer Therapy |
title_short | Repurposing of the Drug Tezosentan for Cancer Therapy |
title_sort | repurposing of the drug tezosentan for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297528/ https://www.ncbi.nlm.nih.gov/pubmed/37367074 http://dx.doi.org/10.3390/cimb45060325 |
work_keys_str_mv | AT ribeiroeduarda repurposingofthedrugtezosentanforcancertherapy AT valenuno repurposingofthedrugtezosentanforcancertherapy |